National Stem Cell, Inc. (OTC: NHGI) is a biotechnology company that has developed a unique infrastructure providing the means to generate revenue through its core reproductive cell and tissue banking operations. These revenue generating processes provide the capacity to help fund additional research and development efforts as the company pursues development of potential stem cell therapies for the treatment of diabetes and cardiac injury through a sponsored research agreement with the Johns Hopkins University School of Medicine's Institute for Cell Engineering (ICE). National Stem Cell’s laboratory services include the collection and storage of reproductive cells and tissues (sperm, embryo and ovum) for use in achieving pregnancy through assisted means and the processing and cryopreservation of stem cells from umbilical cord and peripheral blood.